Chaired by Marisol Touraine, former French Minister of Social Affairs, Health and Women’s Rights, 2012-2017, the Executive Board consists of 13 members who make decisions by consensus.
Chaired by Marisol Touraine, former French Minister of Social Affairs, Health and Women’s Rights, 2012-2017, the Executive Board consists of 13 members who make decisions by consensus.
Chair of the Executive Board
After studying at the Ecole normale supérieure for a degree in economics and social sciences, Marisol Touraine studied at the Institut d'études politiques of Paris and at the prestigious Harvard University in the United States. Advisor to the Prime Minister from 1988 to 1991 on geostrategic issues, she became a member of the Conseil d'Etat in 1991. She then served at political positions at local level and within the French Parliament for several years before being appointed Minister of Social Affairs, Health and Women's Rights (2012-2017). Of particular note in this role was her support to authorize and to assure financial coverage for innovative preventive HIV treatments, as well as her fight for the neutral cigarette pack, acknowledged by the WHO prize in 2016. She is Chair of the Unitaid Executive Board since June 2019.
Representing Brazil /Â Vice-chair of the Executive Board
Born in Curitiba, Paraná, on 12 April 1971. She holds a degree in Law and has been a career diplomat since 1996, after concluding her studies at the Brazilian Diplomatic Academy. She also holds a post-graduate degree in Foreign Trade from Fundação GetĂşlio Vargas, BrasĂlia-DF, and a Masters degree in Public Administration (MPA) from Columbia University, NY. She served at the Brazilian Consulate General in New York, at the Brazilian Embassy to Colombia and at the Brazilian Embassy to the United Kingdom. In the Foreign Ministry headquarters in Brasilia, she has worked as an Assistant to the Director General of the Trade Promotion Department and to the Undersecretary General for Africa, Asia, the Middle East and the Pacific. In the seven years prior to her present appointment, she was the Head of Japan and Korean Peninsula Division, acting Director of East Asia Department, Assistant and Deputy-Chief of Staff to the Secretary-General and subsequentially Director General of the Department of Japan, Korean Peninsula and the Pacific.
Our board consists of 13 members representing Brazil, Chile, France, Norway, the United Kingdom, Spain, the Republic of Korea and Japan, the African Union, non-governmental organizations, communities affected by disease, foundations, and the World Health Organization.
African countries / Board member
African countries / Alternate
Brazil / Alternate
Chile / Board member
Chile / Alternate
Communities living with the diseases / Board member
Communities living with the diseases / Alternate
Foundations / Board member
Foundations / Alternate
France / Board member
France / Alternate
Japan / Board member
Japan / Alternate
NGOs / Board member
NGOS / Alternate
Norway / Board member
Norway / Alternate
Republic of Korea / Board member
Republic of Korea / Alternate
Spain / Board member
Spain / Alternate
United Kingdom / Board member
United Kingdom / Alternate
World Health Organization / Board member
World Health Organization / Alternate
Supports Unitaid’s financial planning and management
Terms of reference [PDF]
Advises the Board on strategic planning and core policies, reviews the performance of Unitaid’s portfolio and responds to policy recommendations from expert advisory groups.
Terms of reference [PDF]
An independent, impartial team of experts who provide guidance to Unitaid on proposals submitted for funding and in grant development. Their expertise covers science, public health, health systems, programming, country implementation, market dynamics and health economics
Terms of reference [PDF]
PRC Chair
Andy Gray B Pharm, MSc (Pharm), PhD, FPS, FFIP is a pharmacist whose research interests include policy analysis (in particular, the development and implementation of National Medicines Policies), rational medicines use and the application of antiretroviral therapy in resource-constrained settings. He is a Senior Lecturer in the Division of Pharmacology, Discipline of Pharmaceutical Sciences, School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa. He is also consultant pharmacist (research associate) for the Centre for the AIDS Programme of Research in South Africa (CAPRISA).
PRC Members
Over 30 years of experience in global health, particularly in HIV prevention, sexual and reproductive health, and health systems strengthening.
From 2015 to 2021, as the Senior Health Advisor and Demography Transition Lead for the United Kingdom Foreign, Commonwealth, and Development Office (FCDO, formerly DFID Department for International Development), she oversaw major health initiatives in both SRHR, disease preparedness and C19. Notably, she created and led the Women’s Integrated Sexual Health (WISH) program, which was the UK’s largest sexual and reproductive health initiative to date, benefiting over 26 countries and receiving up to £320 million in ODA funding.
Bernard Fourie is a medical microbiologist with a career focus in tuberculosis, particularly translational research on rapid diagnostic methods, inhaled therapies and vaccination, and clinical trials of anti-TB medications and other interventions. He is currently attached to the Department of Medical Microbiology at the University of Pretoria and formerly served as the Director of the Tuberculosis Research Institute and of the MRC National TB Research Programme in South Africa. Apart from Unitaid, he has provided expert technical support in the field of tuberculosis over many years to international organizations such as WHO, UNIDO, EDCTP, GIZ, and locally to the South African Medicines Control Council.
Cecilia Oh is a lawyer, with 30 years’ work experience in development and public health. Currently, an independent consultant, her research interests include health technology innovation and access. Until November 2024, she headed the UNDP’s regional health team in Asia Pacific, and was also coordinator of a multi-partner global health project on R&D and access to health technologies for neglected diseases. She has also previously held positions at the World Health Organization and Third World Network, working on the intersections of health, trade and intellectual property.
A PRC Member since 2010, Cheri Grace has 30 years of work experience in a variety of work sectors and organisation types – pharmaceutical industry; corporate finance; grassroots development; academic research, global health consulting. For 15+ years, Cheri has worked as a strategy advisor to aid finance organisations/donors, bringing commercial business knowledge as well as understanding of the strategic direction of various funders, progress and challenges in global health and the wider development aid environment, and experience working in more than 20 aid recipient countries. Previously a Senior Health Advisor in DFID, Cheri led DFID’s work through Product Development Public-Private Partnerships, and supported work in Advance Market Commitments and the broader Access to Medicines agenda. Cheri is also a focal point for the Global Fund Technical Review Panel.
After completing her medical studies in Rome and a postdoctoral fellowship at the National Cancer Institute in Bethesda (USA), Dr Alteri spent 25 years in the pharmaceutical industry, where she was involved in major projects that yielded important drugs such as Gleevec for myeloid leukaemia, Coartem for malaria and Reyataz for HIV-AIDS. In 2012 she joined the European Medicines Agency, where she was Head of Human Medicines R&D support Division, and member of the Executive Board. In these roles, Dr Alteri was part of many high impact EMA’s initiatives, from the transparency of clinical trial data to the development of regulatory science strategy to 2025. Dr Alteri is currently a member of the Scientific Committee and faculty of the master course in Drug Discovery & Clinical Development of the University of Geneva, and the Scientific Committee of Europe-Developing Countries Clinical Trial Partnership (EDCTP)- Global Health.
Tim Farley is a medical statistician with over 40 years experience in clinical and epidemiological research on medical devices, diagnostics, pharmaceutical products and public health interventions. During 30 years with the World Health Organization in Geneva he was involved in multi-national research in sexual and reproductive health with particular focus on the needs of women and men in developing countries. This included development and assessment of novel contraceptive methods, assessing the safety of established contraceptive products, and accelerating development and implementation of new HIV prevention interventions. He led research on the prevention of mother-to-child transmission of HIV during breastfeeding, developed access strategies for woman-controlled HIV prevention methods, and coordinated implementation of voluntary medical male circumcision programs. After leaving WHO in 2011 he founded a statistics and strategy consulting company near Geneva whose clients include international organizations and foundations, academic institutions and commercial entities. Tim hold a PhD in Statistics from the University of Kent, UK and is a professionally qualified Chartered Statistician.
Current Position: Independent consultant ; senior instructor, course developer, and strategic advisor
Areas of expertise: Health and pharmaceutical supply chain such as supply/demand planning including new product introduction, quantification, procurement, warehousing, transport/distribution, and waste management ; governance, regulatory, human resources, costing and funding, and data visibility and usage) ; country readiness and supply chain maturity.
Education and degrees: MSc in Finance ; MBA in supply chain
Gilles Raguin is a medical doctor, trained in internal medicine and infectious diseases, and a global health specialist with more than 20 years of experience with hospital work, governmental and non-governmental organizations.Combining a very good knowledge of global health actors and funders with a strong experience in clinical practice, humanitarian aid and technical expertise, Dr Raguin is particularly experienced in the fields of infectious diseases, global health security and humanitarian health in resource limited countries.
Dr. Giorgio Roscigno is a senior and passionate public health specialist with a very long experience in the private and public sectors. He has been working as medical doctor from 1972 to 1982 in Ethiopia Sudan DRC Algeria and Italy. In 1982 he joined the pharmaceutical Industry and worked in Switzerland France the UK and Italy. He left the Industry in 2000: during this period he developed up to FDA approval all the fixed dose combinations for TB, the first nontoxic drug for Sleeping Sickness and Rifapentine. From 2000 to 2014 he has been involved as Founder and CEO of the Global Alliance for TB (2000/2003); FIND (2003/2013) , The African Society for Laboratory Medicine( COO 2013/2014) and NEXT2PEOPLE ( Executive Chair 2015 -now). Dr. Roscigno has been actively involved in the creation of the Stop TB Partnership and covered overtime positions in the Board and chaired Working Groups in Drugs and Diagnostics.
Jennifer Daily has 20+ years of specialized expertise in health diagnostics and devices, market analysis, and technology access strategies for global health. As an independent consultant, she has served as a trusted advisor to leading organizations, developing market-based investment strategies across multiple disease areas, and shaping global health policies. Her global health experience spans the spectrum from product development and regulatory processes to regional manufacturing and country implementation strategies. Jen holds an MBA from Harvard Business School and combines business/finance acumen with hands-on public health implementation experience.
Chilobe M. Kambikambi is a seasoned global health leader with over 20 years of experience in HIV, maternal and child health, gender equity, and social protection. She holds a Master of Public Health. Chilobe has led large-scale, donor-funded programs in Zambia, managing strategic partnerships, operations, and evidence-based interventions with organizations such as Project HOPE and Save the Children. Known for her expertise in participatory approaches and evidence-based programming, she has advanced inclusive, community-driven health solutions. She currently serves on the Technical Review Committee for ViiV Healthcare’s Positive Action, bringing expertise in HIV programming, structural health equity, and human rights-based approaches.
Lulu Muhe is an adjunct professor of pediatrics and Child Health in Addis Ababa University, Ethiopia since 2015. Before that he worked with the World Health Organization in Geneva and in AFRO in the areas of pediatric infectious diseases such as HIV, malaria, tuberculosis, diarrhea and pneumonia mainly supporting research, policy development and capacity building, monitoring and evaluation in many developing countries.
Nelson Otwoma is a Social Scientist with over 20 years’ public health experience, mainly working directly with civil society organizations and affected communities affected with HIV, TB and related coinfections and comorbidities. He is currently the Director at the National Network of PLHAs in Kenya (NEPHAK) where he works to provide professional, accountable, committed and strategic leadership for the communities’ voice and visibility. Nelson has excellent understanding of the science of HIV and TB as well as the global policies guiding the HIV and TB response and the hands on experience in designing and implementing interventions for achieving the TB/HIV epidemic control. He has been a key leader in designing and promoting Community Engagement (CE) through Community Systems Strengthening (CSS) and helping with the interfacing with the wider Health Systems Strengthening (HSS). This has enhanced his knowledge in health systems, including health policy, health and community systems strengthening and the partnership that drive public and private sector healthcare. This has also given him an excellent opportunity for engaging in the M&E systems, including design and appraisal of M&E indicators and systems; selection and definition of indicators and baselines; verification; reporting; evaluating public health impact and value for money and impact assessment.
Dr Patricia Graves is an expert technical advisor on control and elimination of malaria and other vector borne diseases. She has long-term in-country
applied research and project management experience and has done extensive short-term consulting and policy advisory roles in the Pacific, Asia and Africa. Her expertise is in epidemiology, public health, mosquito control, diagnostics, surveillance, monitoring/evaluation, health information systems and training, in partnership with endemic country governments and donor agencies.”
Paulyne Wairimu, who chairs the African Medical Devices Forum, is a public health expert with a Master of Advanced Studies in International Relations from the Geneva Graduate Institute. She possesses over 15 years of extensive experience in regulatory system strengthening.
Dr Sa’adatu Talatu Sule is an obstetrician/gynaecologist and public health practitioner who has worked as a reproductive health specialist with Nigerian and international institutions, organisations and donors including Ahmadu Bello University, various NGOs and the United Nations System.
Seasoned nurse-midwife and public health specialist with over 25 years of experience leading and advising health development programs across Africa and Asia. Extensive background in HIV/AIDS, reproductive, maternal, newborn, child and adolescent health (RMNCAH), and health systems strengthening, with a track record of managing multi-country initiatives and building capacity in low-resource settings. Recognized for strategic leadership in program design and scale-up, as well as effective collaboration with governments, NGOs, and multilateral donors (USAID, PEPFAR, Global Fund, GAVI).